EAM Global Investors LLC lowered its stake in shares of Mirati Therapeutics Inc (NASDAQ:MRTX) by 16.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 24,260 shares of the biotechnology company’s stock after selling 4,839 shares during the quarter. EAM Global Investors LLC’s holdings in Mirati Therapeutics were worth $1,143,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently made changes to their positions in MRTX. Legal & General Group Plc bought a new stake in Mirati Therapeutics during the second quarter worth about $150,000. Quantitative Systematic Strategies LLC bought a new stake in Mirati Therapeutics during the second quarter worth about $214,000. Renaissance Technologies LLC bought a new stake in Mirati Therapeutics during the second quarter worth about $227,000. United Services Automobile Association bought a new stake in Mirati Therapeutics during the second quarter worth about $250,000. Finally, Kalos Management Inc. bought a new stake in Mirati Therapeutics during the second quarter worth about $252,000.

Several equities research analysts recently commented on MRTX shares. Cann reissued a “buy” rating and set a $62.00 price objective on shares of Mirati Therapeutics in a research note on Tuesday, October 30th. Cowen reissued a “buy” rating on shares of Mirati Therapeutics in a research note on Thursday, September 27th. Jefferies Financial Group reissued a “hold” rating and set a $37.00 price objective on shares of Mirati Therapeutics in a research note on Thursday, November 15th. Guggenheim upgraded shares of Mirati Therapeutics from a “neutral” rating to a “buy” rating in a research note on Monday, October 29th. Finally, BidaskClub upgraded shares of Mirati Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, November 8th. Two research analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $54.86.

In other news, CEO Charles M. Baum sold 51,810 shares of the company’s stock in a transaction that occurred on Thursday, August 23rd. The shares were sold at an average price of $57.55, for a total value of $2,981,665.50. Following the transaction, the chief executive officer now owns 102,742 shares in the company, valued at $5,912,802.10. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 4.86% of the company’s stock.

Shares of NASDAQ MRTX opened at $40.43 on Tuesday. The company has a market capitalization of $1.33 billion, a PE ratio of -14.54 and a beta of 1.83. Mirati Therapeutics Inc has a 52-week low of $15.35 and a 52-week high of $65.35.

Mirati Therapeutics (NASDAQ:MRTX) last issued its earnings results on Tuesday, November 6th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.87) by $0.02. On average, research analysts forecast that Mirati Therapeutics Inc will post -3.12 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Mirati Therapeutics Inc (MRTX) Shares Sold by EAM Global Investors LLC” was originally posted by Daily Political and is the property of of Daily Political. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.dailypolitical.com/2018/11/20/mirati-therapeutics-inc-mrtx-shares-sold-by-eam-global-investors-llc.html.

About Mirati Therapeutics

Mirati Therapeutics, Inc, a clinical-stage oncology company, develops targeted therapeutics to address the genetic, epigenetic, and immunological promoters of cancer. The company is involved in developing sitravatinib, an oral spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of solid tumor; and in Phase Ib clinical trial to treat non-small cell lung cancer (NCSLC) patients with CBL, chromosome 4q12, and RET genetic alterations, as well as mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor that is in Phase II clinical trial in combination with durvalumab for the treatment of patients with NSCLC.

Further Reading: Marijuana Stocks Investing Considerations

Want to see what other hedge funds are holding MRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mirati Therapeutics Inc (NASDAQ:MRTX).

Institutional Ownership by Quarter for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.